Retroperitoneal Laparoscopic Radical Nephrectomy Allows Continuation of Peritoneal Dialysis in Patients with End-Stage Renal Disease

2017 ◽  
Vol 37 (3) ◽  
pp. 340-342 ◽  
Author(s):  
Aziz Khambati ◽  
Mary Kate Fitzgerald ◽  
Kent T. Perry ◽  
Robert B. Nadler
Keyword(s):  
Peritoneal Dialysis ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Radical Nephrectomy ◽  
Wound Complications ◽  
Laparoscopic Radical Nephrectomy ◽  
Surveillance Imaging ◽  
Stage Renal Disease ◽  
End Stage

Patient outcomes for retroperitoneal laparoscopic radical nephrectomy (RLRN) in adults on peritoneal dialysis (PD) have not been described in the literature. This is the first series on the successful application of RLRN for renal cell carcinoma (RCC) among adults with end-stage renal disease (ESRD) on PD. In our series of 5 patients, all were able to promptly resume PD, no wound complications were noted at postoperative visits, and no evidence of recurrence was identified on surveillance imaging at follow-up. We propose that RLRN should be considered in PD patients as it allows immediate reinstitution of PD and prevents the morbidity and complications associated with interim hemodialysis.

Transperitoneal Laparoscopic Radical Nephrectomy for Patients With Dialysis-dependent End-stage Renal Disease: An Analysis and Comparison of Perioperative Outcome

Urology ◽  
2010 ◽  
Vol 75 (6) ◽  
pp. 1335-1342 ◽  
Author(s):  
Vincent G. Bird ◽  
John M. Shields ◽  
Mohammed Aziz ◽  
Rosely De Los Santos ◽  
Rajnikanth Ayyathurai ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Radical Nephrectomy ◽  
Perioperative Outcome ◽  
Laparoscopic Radical Nephrectomy ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Effect of dialysis modality on the survival of end-stage renal disease patients starting dialysis in Sabah from 2007 to 2017: a retrospective cohort study

2021 ◽  
Author(s):  
Thamron Keowmani ◽  
Anis Kausar Ghazali ◽  
Najib Majdi Yaacob ◽  
Koh Wei Wong
Keyword(s):  
Cohort Study ◽  
Peritoneal Dialysis ◽  
Confidence Interval ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Retrospective Cohort ◽  
Dialysis Modality ◽  
Stage Renal Disease ◽  
End Stage

Background: The effect of dialysis modality on the survival of end-stage renal disease patients is a major public health interest. Methods: In this retrospective cohort study, all adult end-stage renal disease patients receiving dialysis treatment in Sabah between January 1, 2007 and December 31, 2017 as identified from the Malaysian Dialysis and Transplant Registry were evaluated and followed up through December 31, 2018. The endpoint was all-cause mortality. The observation time was defined as the time from the date of dialysis initiation after the onset of end-stage renal disease to whichever of the following that came first: date of death, date of transplantation, date of last follow-up, date of recovered kidney function, or December 31, 2018. Weighted Cox regression was used to estimate the effect of dialysis modality. Analyses were restricted to patients with complete data on all variables. Results: 1,837 patients began hemodialysis and 156 patients started with peritoneal dialysis, yielding 7,548.10 (potential median 5.48 years/person) and 747.98 (potential median 5.68 years/person) person-years of observation. 3.1% of patients were lost to follow-up. The median survival time was 5.8 years (95% confidence interval: 5.4, 6.3) among patients who started on hemodialysis and 7.0 years (95% confidence interval: 5.9, indeterminate) among those who started on peritoneal dialysis. The effect of dialysis modality was not significant after controlling for confounders. The average hazard ratio was 0.80 (95% confidence interval: 0.61, 1.05) with hemodialysis as a reference. Conclusion: There was no evidence of a difference in mortality between hemodialysis and peritoneal dialysis.

Outcomes of Simultaneous Peritoneal Dialysis and Arteriovenous Fistula Placement in End-Stage Renal Disease Patients

2017 ◽  
Vol 37 (6) ◽  
pp. 658-661 ◽  
Author(s):  
Nosratollah Nezakatgoo ◽  
Albert Ndzengue ◽  
Manhunath Ramaiah ◽  
Elvira O. Gosmanova
Keyword(s):  
Peritoneal Dialysis ◽  
Renal Disease ◽  
Arteriovenous Fistula ◽  
End Stage Renal Disease ◽  
Catheter Insertion ◽  
The Mean ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Peritoneal dialysis (PD) interruption requiring hemodialysis (HD) is not uncommon and its frequently abrupt nature prevents timely creation of permanent HD access and avoidance of central venous catheters (CVC). We retrospectively studied a cohort of 24 end-stage renal disease (ESRD) patients (mean age 50.7 years, 83.3% African-Americans, 58.3% females, time on dialysis interquartile range [IQR] 0 - 65 days) who had simultaneous PD catheter insertion and backup arteriovenous fistula (AVF) creation between January 1, 2012, and December 31, 2013. The primary outcome of interest was the percent of patients receiving HD through the backup AVF at the time of PD interruption. A median (IQR) for PD catheter use after its insertion was 10.5 (2 - 20) days. After the mean follow-up of 19.6 months, 12 patients remained on PD, 2 patients received a kidney transplant, and 1 patient died. The overall AVF patency was 66.7%. A total of 9 (37.5%) patients had PD interruption requiring permanent (8 patients) or temporary (1 patient) HD after the mean (standard deviation [SD]) follow-up of 12.3 (8.2) months. Arteriovenous fistula was used as the initial access in 4 patients, and in 3 patients the original AVF was used after additional surgical revision. Forty-four percent of patients with a backup AVF fistula avoided CVC at the time of PD interruption requiring HD. The simultaneous AVF creation at the time of PD catheter insertion reduced but did not fully eliminate CVC at the time of PD interruption. Larger studies are needed to evaluate the utility of a backup AVF in PD patients.

Bilateral laparoscopic radical nephrectomy in a patient with end stage renal disease

2018 ◽  
Vol 17 (8) ◽  
pp. 279
Author(s):  
F. Dotta ◽  
A. Pacchetti ◽  
F. Balzarini ◽  
G. Mantica ◽  
M. Cerasuolo ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Radical Nephrectomy ◽  
Laparoscopic Radical Nephrectomy ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Predictors of Loss of Residual Renal Function among New Dialysis Patients

2000 ◽  
Vol 11 (3) ◽  
pp. 556-564 ◽  
Author(s):  
LOUISE M. MOIST ◽  
FRIEDRICH K. PORT ◽  
SEAN M. ORZOL ◽  
ERIC W. YOUNG ◽  
TRULS OSTBYE ◽  
...  
Keyword(s):  
Renal Function ◽  
Peritoneal Dialysis ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Residual Renal Function ◽  
Prior History ◽  
History Of ◽  
Stage Renal Disease ◽  
End Stage

Abstract. Residual renal function (RRF) in end-stage renal disease is clinically important as it contributes to adequacy of dialysis, quality of life, and mortality. This study was conducted to determine the predictors of RRF loss in a national random sample of patients initiating hemodialysis and peritoneal dialysis. The study controlled for baseline variables and included major predictors. The end point was loss of RRF, defined as a urine volume <200 ml/24 h at approximately 1 yr of follow-up. The adjusted odds ratios (AOR) and P values associated with each of the demographic, clinical, laboratory, and treatment parameters were estimated using an “adjusted” univariate analysis. Significant variables (P < 0.05) were included in a multivariate logistic regression model. Predictors of RRF loss were female gender (AOR = 1.45; P < 0.001), non-white race (AOR = 1.57; P = <0.001), prior history of diabetes (AOR = 1.82; P = 0.006), prior history of congestive heart failure (AOR = 1.32; P = 0.03), and time to follow-up (AOR = 1.06 per month; P = 0.03). Patients treated with peritoneal dialysis had a 65% lower risk of RRF loss than those on hemodialysis (AOR = 0.35; P < 0.001). Higher serum calcium (AOR = 0.81 per mg/dl; P = 0.05), use of an angiotensin-converting enzyme inhibitor (AOR = 0.68; P < 0.001), and use of a calcium channel blocker (AOR = 0.77; P = 0.01) were independently associated with decreased risk of RRF loss. The observations of demographic groups at risk and potentially modifiable factors and therapies have generated testable hypotheses regarding therapies that may preserve RRF among end-stage renal disease patients.

Sign in / Sign up

Export Citation Format

Share Document